Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
rasagiline mesilate, Quantity: 1.56 mg
Arrotex Pharmaceuticals Pty Ltd
Tablet, uncoated
Excipient Ingredients: citric acid; purified talc; pregelatinised maize starch; silicon dioxide; maize starch; microcrystalline cellulose; stearic acid
Oral
30, 10
(S4) Prescription Only Medicine
Rasagiline is indicated for the symptomatic treatment of idiopathic Parkinsons disease (PD) as monotherapy (without concomitant levodopa/decarboxylase inhibitor therapy) or as adjunct therapy (with concomitant levodopa/decarboxylase inhibitor therapy).
Visual Identification: White to off-white, round, flat bevelled tablets debossed with "C13" on one side and plain on the other side.; Container Type: Blister Pack; Container Material: PA/Al/PVC/Al - polyamide-aluminium foil-polyvinylchloride/aluminium foil; Container Life Time: 30 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2018-01-23